Repare Therapeutics Announces Acquisition of Pol? ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration [Yahoo! Finance]
Gilead Sciences, Inc. (GILD)
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.gilead.com
Company Research
Source: Yahoo! Finance
precision oncology company, today announced a definitive asset purchase agreement for Gilead Sciences, Inc. to acquire Repare's polymerase theta (Pol?) ATPase inhibitor, RP-3467 (the "Gilead Agreement"). "We are pleased to announce this transaction which combines Gilead's leading expertise in oncology research and development with RP-3467, a potential best-in-class Pol? ATPase inhibitor," said Steve Forte, President, Chief Executive Officer and Chief Financial Officer of Repare. "This marks the third and most significant portfolio transaction for Repare this year." Under the terms of the Gilead Agreement, Repare will receive up to $30 million in total consideration, including a $25 million upfront payment, subject to customary holdbacks and adjustments, and an additional $5 million payment upon completion of specified technology transfer activities. On November 14, 2025, Repare announced that it had entered into a definitive arrangement agreement (the "Arrangement Agreement") wi
Show less
Read more
Impact Snapshot
Event Time:
GILD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GILD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
News
- Update: Gilead Sciences to Acquire Repare Therapeutics' Investigational Cancer Treatment; Repare Shares Rise [Yahoo! Finance]Yahoo! Finance
- Gilead Sciences to Present at Upcoming Investor ConferenceBusiness Wire
- Biopharma climbs higher as 9 drugmakers ink ‘pandering' drug price deals with Trump [Yahoo! Finance]Yahoo! Finance
- 3 Biotech Stocks Wall Street Analysts Are Bullish on for 2026 [Yahoo! Finance]Yahoo! Finance
- Gilead Sciences Exercises Option to License Assembly Biosciences' Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes [Yahoo! Finance]Yahoo! Finance
GILD
Earnings
- 10/30/25 - Beat
GILD
Sec Filings
- 12/16/25 - Form 4
- 12/16/25 - Form 4
- 12/15/25 - Form 144
- GILD's page on the SEC website